Monte Rosa 11月9日在ACR Convergence公布MRT-8102临床前数据：NEK7分子胶降解剂抑制NLRP3炎性小体，痛风2期研究GEMINI-1定2026年第四季启动
波士顿消息—Monte Rosa Therapeutics（纳斯达克：GLUE）2026年11月9日宣布，公司在 ACR Convergence 2026 大会上公布 MRT-8102 的临床前数据。该大会于11月6日至11日在佛罗里达州奥兰多举行；MRT-8102 是一款靶向 NEK7 的口服分子胶降解剂。
据公司公布，海报题为《MRT-8102，一种可口服的 NEK7 选择性分子胶降解剂，抑制 NLRP3 炎性小体激活并在兔痛风性关节炎模型中显示疗效》，编号1082，由公司生物学总监 Philippe Pagni 博士于11月9日美东时间10时30分至12时30分在海报环节 B「先天免疫」中展示。数据称，MRT-8102 在人体实验系统中抑制了 NLRP3 炎性小体激活，并在兔痛风性关节炎模型中显示抗炎活性；在以单钠尿酸盐（MSU）或二水焦磷酸钙（CPPD）晶体刺激的人巨噬细胞中，MRT-8102 降低了 caspase-1 活性，公司称这支持其应对痛风与假性痛风中晶体诱导炎症的潜力。
公司表示，评估 MRT-8102 用于痛风患者的2期研究 GEMINI-1 预计于2026年第四季度启动，将评估急性发作处理后对发作复发的预防，初步数据预计于2027年下半年公布。Monte Rosa 在公告中介绍，公司是一家临床阶段生物技术公司，开发新型分子胶降解剂药物。
Monte Rosa Presents Preclinical Data for MRT-8102 at ACR Convergence on November 9: the NEK7 Molecular Glue Degrader Inhibited NLRP3 Inflammasome Activation, With the GEMINI-1 Phase 2 Gout Study to Start in the Fourth Quarter of 2026
BOSTON — Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE) announced on November 9, 2026, the presentation of preclinical data at ACR Convergence 2026, held November 6–11 in Orlando, Florida, showing that MRT-8102, an orally bioavailable NEK7-directed molecular glue degrader, inhibited NLRP3 inflammasome activation in human experimental systems and reduced inflammation in a rabbit model of gouty arthritis.
The poster, titled "MRT-8102, an Orally Bioavailable NEK7-Selective Molecular Glue Degrader, Suppresses NLRP3 Inflammasome Activation and Demonstrates Efficacy in a Rabbit Model of Gouty Arthritis" (Poster #1082), was presented by Philippe Pagni, Ph.D., Director of Biology, during Poster Session B, "Innate Immunity," on November 9 from 10:30 a.m. to 12:30 p.m. Eastern time. The company said MRT-8102 reduced caspase-1 activity in human macrophages stimulated with monosodium urate (MSU) or calcium pyrophosphate dihydrate (CPPD) crystals, supporting its potential to address crystal-induced inflammation in gout and pseudogout.
The company said GEMINI-1, a Phase 2 study of MRT-8102 in patients with gout, is expected to initiate in the fourth quarter of 2026, will evaluate prevention of flare recurrence following acute flare management, and has initial data expected in the second half of 2027. In the release, Monte Rosa described itself as a clinical-stage biotechnology company developing novel molecular glue degrader-based medicines.
https://www.morningstar.com/news/globe-newswire/9872774/monte-rosa-therapeutics-presents-preclinical-data-at-acr-convergence-2026-on-the-potential-of-mrt-8102-in-gout （Monte Rosa 2026年11月9日经 GlobeNewswire 发布的临床前数据公告）
科学
—-
发布：GSM·美国（发布链接）
图片来源：Wikipedia/Wikimedia Commons 词条主图：Monte Rosa
GSM Global · 本篇英文版 English edition of this story
